Journal of Clinical Pathology and Laboratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Clinical Pathology and Laboratory Medicine (2024) Volume 6, Issue 2

The power of antibody screening revolutionizing healthcare

Scherer Perry*

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, US

*Corresponding Author:
Scherer Perry
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, US
Massachusetts General Hospital and Harvard Medical School
US
E-mail:Scher.err@edu.in

Received:25-Mar-2024, Manuscript No. AACPLM-24-131261; Editor assigned: 28-Mar-2024, PreQC No. AACPLM-24-131261(PQ); Reviewed:11-Apr-2024, QC No. AACPLM-24-131261; Revised:16-Apr-2024, Manuscript No. AACPLM-24-131261(R); Published:23-Apr-2024, DOI:10.35841/ aacplm-6.2.197

Citation: Perry S. The power of antibody screening revolutionizing healthcare. J Clin Path Lab Med. 2024;6(2):197

Introduction

Antibody screening, a critical component of modern healthcare, plays a pivotal role in disease diagnosis, treatment, and prevention. This revolutionary technique allows healthcare professionals to identify antibodies in bodily fluids, aiding in the detection of various diseases, tracking immune responses, and even ensuring the safety of blood transfusions. As technology advances, antibody screening continues to evolve, promising more accurate and efficient methods for combating illness and safeguarding public health[1].

Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as viruses, bacteria, or other pathogens. These proteins recognize and bind to specific antigens, marking them for destruction by other immune cells. Antibody screening involves the detection and measurement of these antibodies in bodily fluids, such as blood or saliva, to assess immune status and diagnose infections or autoimmune diseases[2].

Antibody screening plays a crucial role in diagnosing infectious diseases, such as HIV, hepatitis, and COVID-19. By detecting antibodies produced in response to these pathogens, healthcare providers can confirm the presence of an infection, determine its stage, and monitor the body's immune response. This information is invaluable for guiding treatment decisions and assessing the effectiveness of therapies over time[3].

Moreover, antibody screening enables the early detection of autoimmune disorders, where the immune system mistakenly attacks healthy tissues. Conditions like rheumatoid arthritis, lupus, and celiac disease can be identified through the presence of specific autoantibodies, facilitating timely intervention and management strategies[4].

Blood transfusions are lifesaving procedures commonly performed in medical settings. However, the safety of these transfusions relies on rigorous screening for infectious agents and antibodies. Before blood is transfused to a recipient, it undergoes thorough testing to identify any potential pathogens or incompatible antibodies. This process minimizes the risk of transfusion-related complications, such as transfusion-transmitted infections or adverse immune reactions[5].

Recent advancements in technology have revolutionized antibody screening, making it faster, more sensitive, and cost-effective. Traditional methods, such as enzyme-linked immunosorbent assays (ELISA) and Western blotting, have been augmented by innovative techniques like flow cytometry, multiplex assays, and microarray-based platforms. These high-throughput systems allow for the simultaneous detection of multiple antibodies, enhancing efficiency and throughput in clinical laboratories[6].

Furthermore, the advent of recombinant DNA technology has enabled the production of monoclonal antibodies, which are highly specific and uniform in their binding properties. These monoclonal antibodies serve as invaluable tools in diagnostic assays, therapeutic interventions, and biomedical research[7].

Despite its numerous benefits, antibody screening still faces several challenges, including variability in assay sensitivity and specificity, as well as the emergence of new infectious agents and antibody variants. Additionally, the interpretation of screening results requires careful consideration of factors such as patient demographics, clinical history, and assay limitations[8].

Looking ahead, researchers are exploring novel approaches to enhance the accuracy and reliability of antibody screening. This includes the development of advanced biosensors, artificial intelligence algorithms for data analysis, and point-of-care testing devices for rapid and decentralized diagnostics. By leveraging these technological innovations, healthcare providers can continue to improve patient outcomes and effectively combat infectious diseases on a global scale[9].

Antibody screening represents a cornerstone of modern medicine, providing invaluable insights into immune function, disease diagnosis, and therapeutic interventions. From identifying infectious agents to monitoring autoimmune responses and ensuring the safety of blood transfusions, this powerful technique has revolutionized healthcare practices worldwide. As technology continues to advance, the future of antibody screening holds promise for even greater precision, efficiency, and accessibility, ultimately enhancing our ability to safeguard public health and improve patient care [10].

References

  1. Breitling F, Dubel S, Seehaus T, et al. A surface expression vector for antibody screening. Gene. 1991;104(2):147-53.

    2. Indexed at, Google Scholar, Cross Ref

  2. Howell WM, Carter V, Clark B. The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques. J Clin Pathol. 2010;63(5):387-90.

    3. Indexed at, Google Scholar, Cross Ref

  3. Lueking A, Horn M, Eickhoff H, et al. Protein microarrays for gene expression and antibody screening. Anal Biochem. 1999;270(1):103-11.

    4. Indexed at, Google Scholar, Cross Ref

  4. Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics. 2003;3(1):56-63.

    5. Indexed at, Google Scholar, Cross Ref

  5. Bromilow IM, Adams KE, Hope J, et al. Evaluation of the ID?gel test for antibody screening and identification. Transfus Med. 1991;1(3):159-61.

    6. Indexed at, Google Scholar, Cross Ref

  6. Seah YF, Hu H, Merten CA. Microfluidic single-cell technology in immunology and antibody screening. Mol Asp Med. 2018;59:47-61.

    7. Indexed at, Google Scholar, Cross Ref

  7. Lau FY, Wong R, Chan NP, et al. Provision of phenotype-matched blood units: no need for pre-transfusion antibody screening. Haematologica. 2001;86(7):742-8.

    8. Indexed at, Google Scholar

  8. Boral LI, Hill SS, Apollon CJ, et al. The type and antibody screen, revisited. Am J Clin Pathol. 1979;71(5):578-81.

    9. Indexed at, Google Scholar, Cross Ref

  9. Lander JJ, Gitnick GL, Gelb LH, et al. Anticore antibody screening of transfused blood. Vox Sanguinis. 1978;34(2):77-80.

    10. Indexed at, Google Scholar, Cross Ref

  10. Bayer R, Levine C, Wolf SM. HIV antibody screening: An ethical framework for evaluating proposed programs. Jama. 1986;256(13):1768-74.

    11. Indexed at, Google Scholar, Cross Ref

Get the App